Maschmann, Raíra Mesquita
De Jesus, Rafaela Gomes
Werutsky, Gustavo
Rebelatto, Taiane Francieli
Queiroz, Geraldo
Simon, Sergio Daniel
Bines, José
Barrios, Carlos Henrique Escosteguy
Rosa, Daniela Dornelles http://orcid.org/0000-0002-6196-1919
Funding for this research was provided by:
Programa Nacional de Apoio à Atenção Oncológica (25000.173.901/2013–73)
Article History
Received: 12 February 2022
Accepted: 9 November 2022
First Online: 31 December 2022
Declarations
:
: RMM, RGJ, GW, TFR, GQ, SDS, JB, DDR have nothing to disclose. CHB declares no relevant conflicts of interest under consideration for publication. CHB reports grants/research support: (to the institution) Pfizer, Novartis, Amgen, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Roche/Genentech, Lilly, Sanofi, Taiho Pharmaceutical, Mylan, Merrimack, Merck, AbbVie, Astellas Pharma, BioMarin, Bristol-Myers Squibb, Daiichi Sankyo, Abraxis Biosciences, AB Science, Asana Biosciences, Medivation, Exelixis, ImClone Systems, LEO Pharma, Millennium, Merck KGaA, Shanghai Henlius Biotech, Polyphor, PharmaMar. Advisory Boards and Consulting: Boehringer-Ingelheim, GSK, Novartis, Pfizer, Roche/Genentech, Eisai, Bayer, MSD, Astra Zeneca, Zodiac, Lilly, Sanofi.
: This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of Hospital Moinhos de Vento (Date September, 18<sup>th</sup>, 2015 /No 1.234.499).”
: Informed consent was obtained from all individual participants included in the study.